TY - JOUR
T1 - Mitochondrial intermediate peptidase and the yeast frataxin homolog together maintain mitochondrial iron homeostasis in Saccharomyces cerevisiae
AU - Branda, Steven S.
AU - Yang, Zhi Yong
AU - Chew, Anne
AU - Isaya, Grazia
N1 - Funding Information:
We thank A.L. Horwich, R. Labbe-Bois, G. Schatz, B.L. Trumpower, M.P. Yaffe, M. Carlson, P. Novick, J.D. Friesen and F. Taroni for reagents, W. Sakati and S. Sterling for technical assistance, and W.A. Fenton, F. Kalousek and M. Robinson for discussions. Iron determinations were performed by the Clinical Chemistry Laboratory at the Yale New Haven Hospital and by D.S. Ross in the Department of Plant and Soil Science at the University of Vermont. Statistical analysis was performed by S. Pankratz in the Department of Biostatistics at the Mayo Clinic. This work was supported by a grant from the Muscular Dystrophy Association and grant AG15709 from the National Institutes of Health.
PY - 1999
Y1 - 1999
N2 - Friedreich's ataxia (FRDA) is a neurodegenerative disease typically caused by a deficiency of frataxin, a mitochondrial protein of unknown function. In Saccharomyces cerevisiae, lack of the yeast frataxin homolog (YFH1 gene, Yfh1p polypeptide) results in mitochondrial iron accumulation, suggesting that frataxin is required for mitochondrial iron homeostasis and that FRDA results from oxidative damage secondary to mitochondrial iron overload. This hypothesis implies that the effects of frataxin deficiency could be influenced by other proteins involved in mitochondrial iron usage. We show that Yfh1p interacts functionally with yeast mitochondrial intermediate peptidase (OCT1 gene, YMIP polypeptide), a metalloprotease required for maturation of ferrochelatase and other iron-utilizing proteins. YMIP is activated by ferrous iron in vitro and loss of YMIP activity leads to mitochondrial iron depletion, suggesting that YMIP is part of a feedback loop in which iron stimulates maturation of YMIP substrates and this in turn promotes mitochondrial iron uptake. Accordingly, YMIP is active and promotes mitochondrial iron accumulation in a mutant lacking Yfh1p (yfh1Δ), while genetic inactivation of YMIP in this mutant (yfh1Δoct1Δ) leads to a 2-fold reduction in mitochondrial iron levels. Moreover, overexpression of Yfh1p restores mitochondrial iron homeostasis and YMIP activity in a conditional oct1(ts) mutant, but does not affect iron levels in a mutant completely lacking YMIP (oct1Δ). Thus, we propose that Yfh1p maintains mitochondrial iron homeostasis both directly, by promoting iron export, and indirectly, by regulating iron levels and therefore YMIP activity, which promotes mitochondrial iron uptake. This suggests that human MIP may contribute to the functional effects of frataxin deficiency and the clinical manifestations of FRDA.
AB - Friedreich's ataxia (FRDA) is a neurodegenerative disease typically caused by a deficiency of frataxin, a mitochondrial protein of unknown function. In Saccharomyces cerevisiae, lack of the yeast frataxin homolog (YFH1 gene, Yfh1p polypeptide) results in mitochondrial iron accumulation, suggesting that frataxin is required for mitochondrial iron homeostasis and that FRDA results from oxidative damage secondary to mitochondrial iron overload. This hypothesis implies that the effects of frataxin deficiency could be influenced by other proteins involved in mitochondrial iron usage. We show that Yfh1p interacts functionally with yeast mitochondrial intermediate peptidase (OCT1 gene, YMIP polypeptide), a metalloprotease required for maturation of ferrochelatase and other iron-utilizing proteins. YMIP is activated by ferrous iron in vitro and loss of YMIP activity leads to mitochondrial iron depletion, suggesting that YMIP is part of a feedback loop in which iron stimulates maturation of YMIP substrates and this in turn promotes mitochondrial iron uptake. Accordingly, YMIP is active and promotes mitochondrial iron accumulation in a mutant lacking Yfh1p (yfh1Δ), while genetic inactivation of YMIP in this mutant (yfh1Δoct1Δ) leads to a 2-fold reduction in mitochondrial iron levels. Moreover, overexpression of Yfh1p restores mitochondrial iron homeostasis and YMIP activity in a conditional oct1(ts) mutant, but does not affect iron levels in a mutant completely lacking YMIP (oct1Δ). Thus, we propose that Yfh1p maintains mitochondrial iron homeostasis both directly, by promoting iron export, and indirectly, by regulating iron levels and therefore YMIP activity, which promotes mitochondrial iron uptake. This suggests that human MIP may contribute to the functional effects of frataxin deficiency and the clinical manifestations of FRDA.
UR - http://www.scopus.com/inward/record.url?scp=0032970156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032970156&partnerID=8YFLogxK
U2 - 10.1093/hmg/8.6.1099
DO - 10.1093/hmg/8.6.1099
M3 - Article
C2 - 10332043
AN - SCOPUS:0032970156
SN - 0964-6906
VL - 8
SP - 1099
EP - 1110
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 6
ER -